3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Myeloid
1
Conditions
Melanoma
11
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
10
Carcinoma, Renal Cell
4
Leukemia, Myeloid, Chronic-Phase
3
Kidney Neoplasms
3
Neoplasm Metastasis
2
Lymphoma
2
Leukemia
2
Hepatitis B, Chronic
2
Carcinoma, Hepatocellular
2
Uveal Melanoma
1
Unspecified Adult Solid Tumor, Protocol Specific
1
Thrombocytosis
1
Thrombocythemia, Essential
1
Squamous Cell Carcinoma of Head and Neck
1
Skin Neoplasms
1
Sezary Syndrome
1
Recurrence
1
Primary Myelofibrosis
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precancerous Conditions
1
Polycythemia Vera
1
Ovarian Neoplasms
1
Neurofibromatosis 1
1
Neurofibroma, Plexiform
1
Neurofibroma
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Mycosis Fungoides
1
Meningeal Carcinomatosis
1
Interventions
fludarabine phosphate
21
Cyclophosphamide
20
Peripheral Blood Stem Cell Transplantation
19
Busulfan
16
Tacrolimus
14
Whole-Body Irradiation
12
Methotrexate
12
Mycophenolic Acid
11
Cyclosporine
11
Antilymphocyte Serum
10
fludarabine
6
Filgrastim
6
peginterferon alfa-2a
5
ruxolitinib
4
Radiotherapy
4
Methylprednisolone
4
Melphalan
4
Flow Cytometry
4
Etoposide
4
Decitabine
4
Aspirin
4
Stem Cell Transplantation
3
Injections
3
Cytogenetic Analysis
3
Cytarabine
3
Biopsy
3
Azacitidine
3
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
3
merphos
2
aldesleukin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Thrombocythemia, Essential
×
peginterferon alfa-2b
×
Clear all
NCT01387763
2022-04-27
DALIAH
Odense University Hospital
Phase 3
Completed
202 enrolled